artemotil

Artecef B.V. was a Dutch pharmaceutical company primarily known for the development and commercialization of Artemotil (beta-arteether), a semi-synthetic derivative of artemisinin. Developed in collaboration with the World Health Organization (WHO), Artemotil was specifically designed as an injectable treatment for severe malaria, particularly in pediatric populations. The company focused on addressing the global health challenge of multi-drug resistant Plasmodium falciparum malaria. While the product reached the market and received regulatory approvals in various regions, the company is no longer active as an independent entity.